YCH1899 (5 mg/kg, intravenous injection ) has a moderate clearance rate in rats[1].
YCH1899 overcomes acquired Talazoparib resistance and has a significant regression of tumor volume in MDA-MB-436/OP (6.25, 12.5, and 25 mg/kg, orally, once a day for 27 days) and Capan-1/R-in vivo xenografts (12.5 and 25 mg/kg, orally, once a day for 21 days ) [1].
| Animal Model: | MDA-MB-436/OP xenografts and Capan-1/R-in vivo xenografts mice[1] |
| Dosage: | 12.5 and 25 mg/kg |
| Administration: | Oral administration |
| Result: | Inhibited MDA-MB-436/OP xenografts tumor growth with T/C of 36.74% and 15.29% at 12.5 and 25 mg/kg
Inhibited Capan-1/R xenografts tumor growth with T/C of 48.92% and 13.87% at 12.5 and 25 mg/kg.
|
| Animal Model: | rats[1] |
| Dosage: | 5 mg/kg |
| Administration: | Intravenous injection |
| Result: | Had a moderate clearance rate (24.5 mL/min/kg) and half-life (3.25 h). |
![4-(3-(3-(5-bromofuran-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one Structure](https://www.chemicalbook.com/CAS/20240320/GIF/3032451-66-1.gif)